Novartis: positive phase III results in breast cancer.
(CercleFinance.com) - A phase III trial has showed that Kisqali significantly prolonged progression-free survival in women with advanced or metastatic breast cancer, Novartis said.
The study in premenopausal or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer demonstrated a median progression-free survival of 23.8 months compared to 13 months for tamoxifen or an aromatase inhibitor plus goserelin.
Pre-menopausal breast cancer is a more aggressive disease than post-menopausal breast cancer, and the leading cause of cancer death in women aged 20 to 59.
Novartis presented the data at the 2017 San Antonio Breast Cancer Symposium.
Novartis also said this morning that it has initiated its cash tender offer to purchase all of the outstanding ordinary shares and ADS of radiopharmaceutical company Advanced Accelerator Applications, whose acquisition was first announced in October.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
The study in premenopausal or perimenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer demonstrated a median progression-free survival of 23.8 months compared to 13 months for tamoxifen or an aromatase inhibitor plus goserelin.
Pre-menopausal breast cancer is a more aggressive disease than post-menopausal breast cancer, and the leading cause of cancer death in women aged 20 to 59.
Novartis presented the data at the 2017 San Antonio Breast Cancer Symposium.
Novartis also said this morning that it has initiated its cash tender offer to purchase all of the outstanding ordinary shares and ADS of radiopharmaceutical company Advanced Accelerator Applications, whose acquisition was first announced in October.
Copyright (c) 2017 CercleFinance.com. All rights reserved.